(HRMY) Harmony Biosciences Holdings - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4131971040
Stock: Sleep Medications, Neurological Therapies, Rare Disease Treatments
Total Rating 35
Risk 91
Buy Signal -0.47
| Risk 5d forecast | |
|---|---|
| Volatility | 40.8% |
| Relative Tail Risk | -10.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.43 |
| Alpha | -30.93 |
| Character TTM | |
|---|---|
| Beta | 0.622 |
| Beta Downside | -0.091 |
| Drawdowns 3y | |
|---|---|
| Max DD | 53.95% |
| CAGR/Max DD | -0.24 |
EPS (Earnings per Share)
Revenue
Description: HRMY Harmony Biosciences Holdings March 05, 2026
Harmony Biosciences Holdings, Inc. (HRMY) is a commercial-stage pharmaceutical company. It specializes in therapies for rare and other neurological diseases.
The companys primary commercial product is WAKIX (pitolisant), used for excessive daytime sleepiness in adult narcolepsy patients. This product addresses a chronic neurological condition affecting the brains ability to control sleep-wake cycles.
Harmony Biosciences has multiple drug candidates in its pipeline. Pitolisant is in Phase 3 trials for Prader-Willi Syndrome and Phase 2 for Myotonic Dystrophy. Other pipeline assets include BP1.15205 for narcolepsy, HBS-102 (a melanin-concentrating hormone receptor type 1 antagonist), ZYN-002 for Fragile X Syndrome and 22q Deletion Syndrome, and EPX-100 and EPX-200 for various epileptic encephalopathies. The pharmaceutical sector often involves lengthy and costly development cycles for new drugs, with significant attrition rates at each clinical trial phase.
For more detailed financial and market analysis, consider researching HRMY on ValueRay.
Headlines to watch out for
- WAKIX sales growth drives revenue
- Pipeline development success impacts future revenue
- Regulatory approval for new indications expands market
- Competition from new treatments threatens market share
Piotroski VR‑10 (Strict, 0-10) 7.5
| Net Income: 158.7m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.27 > 0.02 and ΔFCF/TA 5.47 > 1.0 |
| NWC/Revenue: 75.41% < 20% (prev 56.55%; Δ 18.86% < -1%) |
| CFO/TA 0.27 > 3% & CFO 348.2m > Net Income 158.7m |
| Net Debt (-512.9m) to EBITDA (251.4m): -2.04 < 3 |
| Current Ratio: 3.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.7m) vs 12m ago 0.82% < -2% |
| Gross Margin: 77.16% > 18% (prev 0.78%; Δ 7.64k% > 0.5%) |
| Asset Turnover: 76.49% > 50% (prev 71.53%; Δ 4.96% > 0%) |
| Interest Coverage Ratio: 15.43 > 6 (EBITDA TTM 251.4m / Interest Expense TTM 14.6m) |
Altman Z'' 5.55
| A: 0.51 (Total Current Assets 907.0m - Total Current Liabilities 252.1m) / Total Assets 1.27b |
| B: 0.13 (Retained Earnings 160.9m / Total Assets 1.27b) |
| C: 0.20 (EBIT TTM 226.1m / Avg Total Assets 1.14b) |
| D: 0.40 (Book Value of Equity 161.2m / Total Liabilities 401.4m) |
| Altman-Z'' Score: 5.55 = AAA |
Beneish M -3.24
| DSRI: 0.96 (Receivables 96.8m/83.0m, Revenue 868.5m/714.7m) |
| GMI: 1.01 (GM 77.16% / 78.06%) |
| AQI: 0.68 (AQ_t 0.28 / AQ_t-1 0.42) |
| SGI: 1.22 (Revenue 868.5m / 714.7m) |
| TATA: -0.15 (NI 158.7m - CFO 348.2m) / TA 1.27b) |
| Beneish M-Score: -3.24 (Cap -4..+1) = AA |
What is the price of HRMY shares?
As of March 21, 2026, the stock is trading at USD 27.72 with a total of 944,780 shares traded.
Over the past week, the price has changed by +0.40%, over one month by -4.94%, over three months by -28.67% and over the past year by -20.57%.
Over the past week, the price has changed by +0.40%, over one month by -4.94%, over three months by -28.67% and over the past year by -20.57%.
Is HRMY a buy, sell or hold?
Harmony Biosciences Holdings has received a consensus analysts rating of 4.33.
Therefore, it is recommended to buy HRMY.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HRMY price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 42 | 51.5% |
| Analysts Target Price | 42 | 51.5% |
HRMY Fundamental Data Overview March 21, 2026
P/E Trailing = 10.262
P/E Forward = 8.4459
P/S = 1.8522
P/B = 1.8494
Revenue TTM = 868.5m USD
EBIT TTM = 226.1m USD
EBITDA TTM = 251.4m USD
Long Term Debt = 143.7m USD (from longTermDebt, last quarter)
Short Term Debt = 86.9m USD (from shortTermDebt, last quarter)
Debt = 239.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -512.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.07b USD (1.61b + Debt 239.6m - CCE 775.3m)
Interest Coverage Ratio = 15.43 (Ebit TTM 226.1m / Interest Expense TTM 14.6m)
EV/FCF = 3.08x (Enterprise Value 1.07b / FCF TTM 347.9m)
FCF Yield = 32.43% (FCF TTM 347.9m / Enterprise Value 1.07b)
FCF Margin = 40.06% (FCF TTM 347.9m / Revenue TTM 868.5m)
Net Margin = 18.27% (Net Income TTM 158.7m / Revenue TTM 868.5m)
Gross Margin = 77.16% ((Revenue TTM 868.5m - Cost of Revenue TTM 198.3m) / Revenue TTM)
Gross Margin QoQ = 71.88% (prev 75.09%)
Tobins Q-Ratio = 0.84 (Enterprise Value 1.07b / Total Assets 1.27b)
Interest Expense / Debt = 1.48% (Interest Expense 3.55m / Debt 239.6m)
Taxrate = 44.83% (18.3m / 40.8m)
NOPAT = 124.7m (EBIT 226.1m * (1 - 44.83%))
Current Ratio = 3.60 (Total Current Assets 907.0m / Total Current Liabilities 252.1m)
Debt / Equity = 0.28 (Debt 239.6m / totalStockholderEquity, last quarter 870.2m)
Debt / EBITDA = -2.04 (Net Debt -512.9m / EBITDA 251.4m)
Debt / FCF = -1.47 (Net Debt -512.9m / FCF TTM 347.9m)
Total Stockholder Equity = 799.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.98% (Net Income 158.7m / Total Assets 1.27b)
RoE = 19.84% (Net Income TTM 158.7m / Total Stockholder Equity 799.7m)
RoCE = 23.97% (EBIT 226.1m / Capital Employed (Equity 799.7m + L.T.Debt 143.7m))
RoIC = 12.86% (NOPAT 124.7m / Invested Capital 969.7m)
WACC = 7.25% (E(1.61b)/V(1.85b) * Re(8.21%) + D(239.6m)/V(1.85b) * Rd(1.48%) * (1-Tc(0.45)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.13%
[DCF] Terminal Value 83.74% ; FCFF base≈296.2m ; Y1≈365.4m ; Y5≈622.3m
[DCF] Fair Price = 223.0 (EV 12.38b - Net Debt -512.9m = Equity 12.90b / Shares 57.8m; r=7.25% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 12.39 | EPS CAGR: 3.01% | SUE: -1.85 | # QB: 0
Revenue Correlation: 96.40 | Revenue CAGR: 32.31% | SUE: 0.56 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.14 | Chg7d=-0.147 | Chg30d=-0.087 | Revisions Net=-2 | Analysts=3
EPS current Year (2026-12-31): EPS=4.79 | Chg7d=-0.710 | Chg30d=-0.586 | Revisions Net=-3 | Growth EPS=+33.2% | Growth Revenue=+17.5%
EPS next Year (2027-12-31): EPS=5.79 | Chg7d=-1.554 | Chg30d=-1.398 | Revisions Net=-2 | Growth EPS=+20.8% | Growth Revenue=+12.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -1.5% (Discount Rate 8.2% - Earnings Yield 9.7%)
[Growth] Growth Spread = +24.9% (Analyst 23.4% - Implied -1.5%)
P/E Forward = 8.4459
P/S = 1.8522
P/B = 1.8494
Revenue TTM = 868.5m USD
EBIT TTM = 226.1m USD
EBITDA TTM = 251.4m USD
Long Term Debt = 143.7m USD (from longTermDebt, last quarter)
Short Term Debt = 86.9m USD (from shortTermDebt, last quarter)
Debt = 239.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -512.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.07b USD (1.61b + Debt 239.6m - CCE 775.3m)
Interest Coverage Ratio = 15.43 (Ebit TTM 226.1m / Interest Expense TTM 14.6m)
EV/FCF = 3.08x (Enterprise Value 1.07b / FCF TTM 347.9m)
FCF Yield = 32.43% (FCF TTM 347.9m / Enterprise Value 1.07b)
FCF Margin = 40.06% (FCF TTM 347.9m / Revenue TTM 868.5m)
Net Margin = 18.27% (Net Income TTM 158.7m / Revenue TTM 868.5m)
Gross Margin = 77.16% ((Revenue TTM 868.5m - Cost of Revenue TTM 198.3m) / Revenue TTM)
Gross Margin QoQ = 71.88% (prev 75.09%)
Tobins Q-Ratio = 0.84 (Enterprise Value 1.07b / Total Assets 1.27b)
Interest Expense / Debt = 1.48% (Interest Expense 3.55m / Debt 239.6m)
Taxrate = 44.83% (18.3m / 40.8m)
NOPAT = 124.7m (EBIT 226.1m * (1 - 44.83%))
Current Ratio = 3.60 (Total Current Assets 907.0m / Total Current Liabilities 252.1m)
Debt / Equity = 0.28 (Debt 239.6m / totalStockholderEquity, last quarter 870.2m)
Debt / EBITDA = -2.04 (Net Debt -512.9m / EBITDA 251.4m)
Debt / FCF = -1.47 (Net Debt -512.9m / FCF TTM 347.9m)
Total Stockholder Equity = 799.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 13.98% (Net Income 158.7m / Total Assets 1.27b)
RoE = 19.84% (Net Income TTM 158.7m / Total Stockholder Equity 799.7m)
RoCE = 23.97% (EBIT 226.1m / Capital Employed (Equity 799.7m + L.T.Debt 143.7m))
RoIC = 12.86% (NOPAT 124.7m / Invested Capital 969.7m)
WACC = 7.25% (E(1.61b)/V(1.85b) * Re(8.21%) + D(239.6m)/V(1.85b) * Rd(1.48%) * (1-Tc(0.45)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.13%
[DCF] Terminal Value 83.74% ; FCFF base≈296.2m ; Y1≈365.4m ; Y5≈622.3m
[DCF] Fair Price = 223.0 (EV 12.38b - Net Debt -512.9m = Equity 12.90b / Shares 57.8m; r=7.25% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 12.39 | EPS CAGR: 3.01% | SUE: -1.85 | # QB: 0
Revenue Correlation: 96.40 | Revenue CAGR: 32.31% | SUE: 0.56 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.14 | Chg7d=-0.147 | Chg30d=-0.087 | Revisions Net=-2 | Analysts=3
EPS current Year (2026-12-31): EPS=4.79 | Chg7d=-0.710 | Chg30d=-0.586 | Revisions Net=-3 | Growth EPS=+33.2% | Growth Revenue=+17.5%
EPS next Year (2027-12-31): EPS=5.79 | Chg7d=-1.554 | Chg30d=-1.398 | Revisions Net=-2 | Growth EPS=+20.8% | Growth Revenue=+12.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = -1.5% (Discount Rate 8.2% - Earnings Yield 9.7%)
[Growth] Growth Spread = +24.9% (Analyst 23.4% - Implied -1.5%)